T

Tianjin Ringpu Bio-Technology Co Ltd
SZSE:300119

Watchlist Manager
Tianjin Ringpu Bio-Technology Co Ltd
SZSE:300119
Watchlist
Price: 18.4 CNY -4.66% Market Closed
Market Cap: 8.5B CNY
Have any thoughts about
Tianjin Ringpu Bio-Technology Co Ltd?
Write Note

Tianjin Ringpu Bio-Technology Co Ltd
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Tianjin Ringpu Bio-Technology Co Ltd
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
T
Tianjin Ringpu Bio-Technology Co Ltd
SZSE:300119
Total Receivables
ÂĄ1.1B
CAGR 3-Years
18%
CAGR 5-Years
15%
CAGR 10-Years
11%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Receivables
ÂĄ3.3B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Receivables
ÂĄ1.1B
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
16%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Receivables
ÂĄ7.5B
CAGR 3-Years
-7%
CAGR 5-Years
3%
CAGR 10-Years
10%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Receivables
ÂĄ13.2B
CAGR 3-Years
19%
CAGR 5-Years
11%
CAGR 10-Years
13%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Receivables
ÂĄ172.9m
CAGR 3-Years
-11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Tianjin Ringpu Bio-Technology Co Ltd
Glance View

Market Cap
8.6B CNY
Industry
Pharmaceuticals

Tianjin Ringpu Bio-technology Co., Ltd. engages in the provision of animal health services. The company is headquartered in Tianjin, Tianjin and currently employs 2,701 full-time employees. The company went IPO on 2010-09-17. The firm operates through two main segments. The Veterinary Use Biological Products segment is mainly involved in the manufacture and sales of poultry vaccines, veterinary use vaccines, biological products for treatment, diagnostic products and other biological products. The Veterinary Preparations segment is mainly involved in the manufacture and sales of chemical preparations, veterinary Chinese medicine and other preparations.

Intrinsic Value
24.46 CNY
Undervaluation 25%
Intrinsic Value
Price
T

See Also

What is Tianjin Ringpu Bio-Technology Co Ltd's Total Receivables?
Total Receivables
1.1B CNY

Based on the financial report for Sep 30, 2024, Tianjin Ringpu Bio-Technology Co Ltd's Total Receivables amounts to 1.1B CNY.

What is Tianjin Ringpu Bio-Technology Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 10Y
11%

Over the last year, the Total Receivables growth was 19%. The average annual Total Receivables growth rates for Tianjin Ringpu Bio-Technology Co Ltd have been 18% over the past three years , 15% over the past five years , and 11% over the past ten years .

Back to Top